Atossa Therapeutics Inc
Research Atossa Therapeutics Inc (ATOS) on Bullrun: market cap USD 26.74M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerATOS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 26.74M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 8.49M
- Free cash flow-USD 9.64M
Valuation Snapshot
latest market cap is USD 26.74M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 34.77M | -USD 29.79M | n/a | -4.04 | USD 41.30M | n/a | USD 39.35M |
| FY2024 | USD 0 | -USD 25.50M | -USD 21.05M | n/a | -3.04 | USD 71.08M | n/a | USD 71.48M |
| FY2023 | n/a | -USD 30.09M | -USD 20.96M | n/a | -0.24 | USD 88.46M | n/a | USD 91.02M |
| FY2022 | n/a | -USD 26.96M | -USD 20.79M | n/a | -0.21 | USD 110.89M | n/a | USD 117.96M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 26.74M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 76.21M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 121.42M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 110.27M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 67.11M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 202.60M | n/a | n/a | n/a |
About Atossa Therapeutics Inc
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Atossa Therapeutics Inc's market cap?
Atossa Therapeutics Inc's market capitalization is USD 26.74M.
What does Atossa Therapeutics Inc do?
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc.